Full coverage· Economy· Updated
Teva R&D Chief Arik Yoz Departs One Week After Strategy Unveiling
Teva Pharmaceuticals announced that Dr. Arik Yoz, its Senior Vice President for Global R&D and Chief Medical Officer, is leaving the company. His departure comes a week after Teva presented its innovative medicines strategy and revenue goals for 2030.
2 newsrooms · 1 language · sincePlus
What happened
- 01Teva's Senior VP of R&D, Dr. Arik Yoz, is departing the company.
- 02His exit follows Teva's presentation of its innovative medicines strategy and 2030 revenue targets.
- 03Dr. David Gardiner will temporarily lead R&D operations.
- 04Teva is actively searching for a permanent replacement for Yoz.
- 05CEO Richard Francis affirmed that Teva's strategic goals remain unchanged.
Dr. David Gardiner will temporarily lead R&D while Teva searches for a permanent replacement. CEO Richard Francis stated that the company's strategy and goals remain unchanged.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- CentreNone
- RightNone
- HarediNone
- ArabNone
- Other2
How it broke
See which of the 2 newsrooms broke it, and who waited